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CSF protein biomarkers predicting longitudinal reduction of CSF
b-amyloid42 in cognitively healthy elders
N Mattsson1,2,3, P Insel1, R Nosheny1, H Zetterberg2,4, JQ Trojanowski5, LM Shaw5, D Tosun1,3 and M Weiner1,3 for the Alzheimer’s
Disease Neuroimaging Initiative
b-amyloid (Ab) plaque accumulation is a hallmark of Alzheimer’s disease (AD). It is believed to start many years prior to symptoms
and is reflected by reduced cerebrospinal fluid (CSF) levels of the peptide Ab1–42 (Ab42). Here we tested the hypothesis that
baseline levels of CSF proteins involved in microglia activity, synaptic function and Ab metabolism predict the development of Ab
plaques, assessed by longitudinal CSF Ab42 decrease in cognitively healthy people. Forty-six healthy people with three to four serial
CSF samples were included (mean follow-up 3 years, range 2–4 years). There was an overall reduction in Ab42 from a mean
concentration of 211–195 pgml 1 after 4 years. Linear mixed-effects models using longitudinal Ab42 as the response variable, and
baseline proteins as explanatory variables (n¼ 69 proteins potentially relevant for Ab metabolism, microglia or synaptic/neuronal
function), identified 10 proteins with significant effects on longitudinal Ab42. The most significant proteins were angiotensin-
converting enzyme (ACE, P¼ 0.009), Chromogranin A (CgA, P¼ 0.009) and Axl receptor tyrosine kinase (AXL, P¼ 0.009). Receiver-
operating characteristic analysis identified 11 proteins with significant effects on longitudinal Ab42 (largely overlapping with the
proteins identified by linear mixed-effects models). Several proteins (including ACE, CgA and AXL) were associated with Ab42
reduction only in subjects with normal baseline Ab42, and not in subjects with reduced baseline Ab42. We conclude that baseline
CSF proteins related to Ab metabolism, microglia activity or synapses predict longitudinal Ab42 reduction in cognitively healthy
elders. The finding that some proteins only predict Ab42 reduction in subjects with normal baseline Ab42 suggest that they predict
future development of the brain Ab pathology at the earliest stages of AD, prior to widespread development of Ab plaques.
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INTRODUCTION
b-amyloid (Ab) plaques is a hallmark of Alzheimer’s disease (AD)
and are reflected by reduced levels of cerebrospinal fluid (CSF)
Ab42.1–3 Reduced CSF Ab42 has high diagnostic accuracy for AD
as determined by autopsy4 and agrees well with the results of
positron emission tomography (PET) using Ab tracers.5–7 Although
somewhat controversial, many believe that biomarkers reflecting
the accumulation of brain Ab in plaques are the earliest detectable
biomarker signs of AD in elders, reaching pathological levels
several years before the development of cognitive symptoms.8
Other hallmarks of AD are axonal degeneration and tangle
pathology, which are reflected by increased CSF tau (total-tau,
T-tau) and phosphorylated tau (P-tau), respectively.9 Reports on
both autosomal-dominant AD8 and late-onset AD10 suggest that
increased CSF T-tau and P-tau levels occur first after widespread
amyloid plaque deposition, evidenced by reduced CSF Ab42 and
amyloid imaging. Currently, possibly aside from the Apolipo-
protein E (APOE) e4 variant,11,12 there are no biomarkers that are
known to predict the development of Ab plaques in people
without familial AD. Biomarkers predicting Ab plaque formation in
humans would be important both for determining individual risk
of Ab pathology and as in vivo evidence linking distinct molecular
pathways to Ab pathology in humans.
Experimental and genetic data have suggested that inflamma-
tion (especially microglial activity13,14) and synaptic function15,16
may be important for Ab production, accumulation and/or
toxicity, but there are little in vivo data supporting such
pathways in humans. However, previous studies have suggested
that some proteins in human CSF may reflect changes in such
pathways.17,18
To our knowledge, no previous study has attempted to
identify protein biomarkers that predict longitudinal Ab plaque
formation in cognitively healthy people. Therefore, the main
goals of this study were to investigate the following a priori
hypotheses using proteins measured in normal controls in
Alzheimer’s Disease Neuroimaging Initiative (ADNI): (1) baseline
levels of CSF proteins involved in Ab metabolism, microglia
activity, synaptic/neuronal function or other AD-related processes
predict longitudinal CSF Ab42 decrease in cognitively healthy
people; (2) baseline levels of some of these proteins may predict
CSF Ab42 decrease even in subjects without Ab plaque pathology
at baseline (reflected by CSF Ab42 levels below an AD-related
cutoff4) and (3) These proteins are less predictive of P-tau and
T-tau changes, according to a model in which P-tau and T-tau
become abnormal downstream of Ab pathology and associated
biomarkers.19
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SUBJECTS AND METHODS
Study design
This was a longitudinal study on the associations between CSF proteins at
baseline and longitudinal changes in CSF Ab42, T-tau and P-tau. Data used
in the preparation of this article were obtained from the ADNI database
(http://adni.loni.ucla.edu/). The ADNI was launched in 2003 by the National
Institute on Aging, the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration, private
pharmaceutical companies and non-profit organizations, as a $60 million,
5-year public–private partnership. The primary goal of ADNI has been to
test whether serial magnetic resonance imaging, PET, other biological
markers, and clinical and neuropsychological assessment can be combined
to measure the progression of mild cognitive impairment (MCI) and early
AD. Determination of sensitive and specific markers of very early AD
progression is intended to aid researchers and clinicians to develop new
treatments and monitor their effectiveness, as well as lessen the time and
cost of clinical trials. The Principal Investigator of this initiative is Michael W
Weiner, MD, VA Medical Center and University of California–San Francisco.
ADNI is the result of efforts of many co-investigators from a broad range of
academic institutions and private corporations, and subjects have been
recruited from over 50 sites across the United States and Canada. The
initial goal of ADNI was to recruit 800 subjects but ADNI has been followed
by ADNI-GO and ADNI-2. To date, these three protocols have recruited over
1500 adults, aged 55–90 years, to participate in the research, consisting of
cognitively normal older individuals, people with early or late MCI and
people with early AD. The follow-up duration of each group is specified in
the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally
recruited for ADNI-1 and ADNI-GO had the option to be followed in
ADNI-2. For up-to-date information, see www.adni-info.org. Written
consent was obtained from all subjects participating in the study
according to the Declaration of Helsinki, and the study was approved by
the institutional review board at each participating site.
Participants
Our study population was 46 ADNI-1 healthy control participants, from
whom longitudinal CSF samples were taken three to four times and
analyzed for Ab42, T-tau and P-tau in a 4-year follow-up assay run, and in
whom baseline samples had been analyzed using multiplex proteomics.
Inclusion/exclusion criteria for ADNI-1 subjects are described in detail at
www.adni-info.org. Briefly, all the control subjects included in ADNI-1 were
between the ages of 55 and 90 years, had completed at least 6 years of
education, were fluent in Spanish or English, were free of any significant
neurologic disease and had CDR scores of 0. APOE genotypes were
determined for all subjects. We also tested 16 ADNI-1 AD dementia
patients, in whom longitudinal CSF samples (taken three to five times) had
been analyzed for Ab42, T-tau and P-tau, and in whom baseline samples
had been analyzed using multiplex proteomics in the same assay runs as
the samples from the healthy controls.
Procedures
The study procedures included lumbar punctures for CSF sampling at
baseline and follow-up approximately every 12 months (the mean total
follow-up 3.1 years, range 1.9–4.2). Procedures for CSF sampling, transport
and storage have been described previously.4 Participants also underwent
repeated medical evaluation and neuropsychological testing. For this
study, we used total scores for mini mental state examination, Alzheimer’s
Disease Assessment Scale-Cognitive Behavior section (ADAS-Cog) and a
modified 13-item version of ADAS-Cog (ADAS-MOD).20 For six subjects
who had undergone 11C-Pittsburgh compound B (PiB)-PET scanning,21 we
included these data to test the concordance between CSF Ab42
measurements and the brain Ab load as estimated by using PiB-PET.
CSF protein measurements
CSF Ab42, T-tau and P-tau were measured at the ADNI Biomarker Core
laboratory at the University of Pennsylvania Medical Center, using the
multiplex xMAP Luminex platform (Luminex, Austin, TX, USA) with the
INNOBIA AlzBio3 kit (Innogenetics, Ghent, Belgium).4
CSF multiplex proteomics was carried out using an xMAP multiplex kit
developed by Rules Based Medicine (MyriadRBM). Details regarding the
assay technology, validation and quality control can be found online
(http://adni.loni.ucla.edu/). In brief, the kit included 159 analytes, selected
for analytes believed to be relevant for a number of different diseases
including cancer, autoimmune disorders and AD. Previous versions of the
kit had been used to explore CSF or plasma proteins in AD.22–24 Seventy-six
analytes were adequately quantifiable in the CSF samples in this study (the
other analytes were mostly below the assay-detection limit or had other
assay limitations as outlined in the assay documentation found online at
http://adni.loni.ucla.edu/). For these, we did a systematic literature review
to find previous evidence of associations with Ab metabolism, microglial
activity, synaptic function or other aspects of AD (See Supplementary
Table 1 for results, including references). We identified 67 analytes of
interest that were included in this study. Some analytes were used after log
transformation as described in the assay documentation. Together with
Ab42, T-tau and P-tau, this resulted in 69 analytes available for each test
described below (baseline Ab42, T-tau or P-tau were excluded in tests of
trajectories of Ab42, T-tau and P-tau, respectively).
Statistical analyses
Potentially confounding effects by age, sex, education and APOE on expla-
natory proteins were evaluated by linear regression. Logistic regression
was used to test whether any demographic parameter was associated with
study drop-out.
Effects of explanatory proteins on longitudinal Ab42, T-tau and P-tau
were tested by using linear mixed-effects models, in which Ab42, T-tau or
P-tau was used as a response variable, and the time from the baseline visit
in years, explanatory protein, the interaction between time and
explanatory protein, age, sex, education and APOE e4 status were included
as fixed effects (rates of change of Ab42, T-tau and P-tau were tested
separately with each explanatory protein). All models included a random
intercept and slope (except some models that would not converge with a
random slope, and therefore only included a random intercept). After
inspection of the correlation within subjects, a compound symmetry
structure was assumed. We assessed the applicability of the linear mixed-
effect model by evaluating (1) linearity of biomarker concentration over
time within subjects, (2) the normality of the model residuals and (3) the
difference between models with and without time as a random effect.
Owing to the large number of proteins tested, we corrected for multiple
comparisons using a false discovery rate correction.
Prognostic discrimination of explanatory proteins for longitudinal Ab42
reduction was also tested by ROC statistics. For this, CSF Ab42 change was
calculated as the relative change over 4 years, estimated using individual
intercepts and slopes from a mixed effect model, adjusted for age, sex,
education and APOE. The cutoff defining Ab42 reduction was determined
by the 25th percentile, and the cutoff for Ab42 stability by the 75th
percentile. Dichotomous Ab42 reduction status was then regressed on
each significant protein separately, using logistic regression. Predicted
probabilities from these models were then used to calculate each protein’s
ability to discriminate Ab decliners from those with stable Ab. This
predictive accuracy was estimated as the area under the ROC curve (AUC).
Each accuracy was cross-validated using a leave-one-out design. Con-
fidence intervals (CIs) for cross-validated accuracies were calculated using
variance estimates from 200 bootstrap resamples. To evaluate the proteins’
collective ability to discriminate Ab decliners from nondecliners, we used
logistic regression with a least absolute shrinkage and selection operator
penalty on the coefficients of the proteins. The least absolute shrinkage
and selection operator penalty was used to simultaneously estimate the
effects of a large number of correlated protein concentrations on Ab
reduction. Results were summarized with predictive accuracy (AUC) and
95% CIs estimated from 200 bootstrap resamples.
Significance was determined at Po0.05 after correction for multiple
comparisons using a false discovery rate correction. All statistics were
performed using R (v. 2.15.2, The R Foundation for Statistical Computing).
The nlme package v.3.1-10525 was used for linear mixed effect models. The
ROCR package v.1.0–226 was used to calculate AUC.
RESULTS
Table 1 summarizes demographics and clinical characteristics. There
were longitudinal reductions in the mini mental state examination
(b¼  0.18, s.e.¼ 0.081, P¼ 0.034) and increases in ADAS-MOD
(b¼ 0.47, s.e.¼ 0.23, P¼ 0.042) but no significant changes in ADAS-
Cog (linear mixed effect models, adjusted for age, sex, education
and APOE). Five subjects progressed to MCI during the study.
In the six subjects in whom PiB-PET data of the brain Ab were
available, CSF Ab42 and PiB-PET measurements were 100% con-
cordant when using previously published cutoffs (Supplementary
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Figure 1), supporting the use of CSF Ab42 to identify brain Ab
accumulation in this study.
Half the study population (n¼ 23, 50%) had three longitudinal
samples and the other half had four longitudinal samples over a
maximum of 4 years of follow-up. There were no significant
associations between the demographic parameters and lack of the
4th sample (age, P¼ 0.51; sex, P¼ 0.10; education, P¼ 0.074; APOE
e4, P¼ 0.53, tested by logistic regression).
Effects of age, sex, education and APOE on CSF proteins
Age, sex, education and APOE were potential confounders of the
relationship between the investigated proteins and Ab42, T-tau
and P-tau. We tested for imbalance using linear regression with
baseline proteins as dependent variables, and age, sex, education
and APOE as independent variables. Higher age was associated
with higher levels of monokine induced by gamma interferon
(Po0.001), CD40 antigen (CD40, P¼ 0.0025), b-2-micro-
globulin (B2M, P¼ 0.026) and tumor necrosis factor receptor 2
(P¼ 0.045); female sex with higher levels of follicle-stimulating
hormone (Po0.001), T-tau (P¼ 0.0081), P-tau (P¼ 0.020) and
leptin (P¼ 0.0099), and lower levels of serum amyloid P-compo-
nent (P¼ 0.001), a-1-microglobulin (P¼ 0.018), ApoD (P¼ 0.024),
immunoglobulin A (P¼ 0.033), monocyte chemotactic protein 1
(P¼ 0.040) and fibrinogen (P¼ 0.042); longer education with
higher levels of tissue inhibitor of metalloproteinases 1 (TIMP1,
Po0.001), plasminogen activator inhibitor 1 (P¼ 0.0049), tumor
necrosis factor receptor 2 (P¼ 0.0073), P-tau (P¼ 0.013), macro-
phage colony-stimulating factor 1 (MCSF, P¼ 0.017), interleukin
(IL)-16 (P¼ 0.018), von Willebrand factor (P¼ 0.020), B2M
(P¼ 0.020), insulin-like growth factor-binding protein 2
(P¼ 0.035) and Clusterin (CLU, P¼ 0.035); APOE e4 with lower
levels of Ab42 (P¼ 0.0070), T-tau (P¼ 0.0014), Osteopontin
(P¼ 0.0078), P-tau (P¼ 0.0098) and chemokine CC-4 (P¼ 0.032).
On the basis of these results, we included age, sex, APOE and
education as covariates in all subsequent analyses.
Baseline CSF proteins associated with baseline CSF Ab42, T-tau
and P-tau
Linear regression was used to test associations between individual
baseline proteins and baseline Ab42, T-tau and P-tau. No proteins
were significantly associated with baseline Ab42, but several
proteins were significantly associated with baseline T-tau, includ-
ing P-tau (Po0.001), Chromogranin A (CgA, Po0.001) and Axl
receptor tyrosine kinase (AXL, Po0.001, Supplementary Table 2).
Proteins predicting longitudinal change in CSF Ab42
The main goal of the study was to test the prediction by baseline
proteins of longitudinal CSF Ab42 (predictions of CSF T-tau and
P-tau were also tested, presented below). See Figure 1 for plots of
longitudinal CSF Ab42, T-tau and P-tau. We tested the prediction
by baseline proteins of longitudinal CSF Ab42 in two ways. First,
we used linear mixed effect models with longitudinal Ab42 as a
continuous variable, including all subjects. Second, we used ROC
statistics as described in the Patients and methods section,
dichotomizing the study population based on relative change in
Ab42 from baseline to 4-year follow-up (using estimated rates
from the linear mixed effect model). To clearly separate the
subjects compared in the ROC statistics, we only compared
subjects with the most and the least Ab42 change (1st and 4th
quartiles of subjects ranked by relative Ab42 change).
Using linear mixed effect models (with continuous Ab42,
including all subjects), 10 proteins had significant effects (See
Table 2 and Figure 2 for the significant proteins, and
Supplementary Table 3 for data on all tested proteins). The most
significant proteins were angiotensin-converting enzyme (ACE),
CgA, AXL, Log TNF-related apoptosis-inducing ligand receptor,
CD40 and MCSF. For all these proteins, high baseline protein levels
predicted reduced Ab42 over time.
For the ROC statistics, we compared subjects showing the most
Ab42 reduction (1st quartile 411.5% reduction from baseline)
with subjects showing the least reduction (4th quartile o4.0%
reduction from baseline). Note that the 11.5% cutoff for Ab42
reduction exceeds the within-run measurement variability of the
xMAP AlzBio3 Ab42 assay and thereby very likely reflects a
biological change.27 By these definitions, 12 subjects had Ab42
reduction (four APOE e4þ , six female subjects, mean age 80 years
(range 73–88, mini mental state examination 29.3 (28–30), ADAS-
Cog 5.7 (1.7–15), ADAS-MOD 8.9 (1.7–18)) and 12 subjects had
stable Ab42 (one APOE e4þ , six female subjects, aged 78 years
(72–87), mini mental state examination 29.6 (20–30), ADAS-Cog
6.8 (2.3–10), ADAS-MOD 10 (4.0–15)). In the ROC analysis, 11
proteins significantly predicted Ab42 reduction (Figure 3 and
Supplementary Table 4). These proteins largely overlapped with
the proteins identified by the linear mixed effect analysis
described above. Highest AUC were seen for ACE (AUC¼ 0.87
(95% CI 0.72–1.00)), B2M (AUC¼ 0.83 (95% CI 0.67–0.98)) and CgA
(AUC¼ 0.83 (95% CI 0.67–0.98)). All identified significant proteins
were higher at baseline in subjects with longitudinal Ab42
reduction, except Cystatin C, which was lower in subjects with
longitudinal Ab42 reduction.
Combination of biomarkers to predict CSF Ab42 change
We used logistic regression with a least absolute shrinkage and
selection operator penalty to test whether a combination of
baseline proteins could be used to predict CSF Ab42 change.
When all proteins were included, it resulted in an 81% (95% CI 62–
100%) cross-validated accuracy to discriminate between subjects
with the most Ab42 reduction (1st quartile 411.5% reduction
from baseline) and subjects with the least reduction (4th quartile
o4.0% reduction from baseline). Thus, we could not find evidence
that combining biomarkers was superior to using the best
individual biomarkers for the prediction of CSF Ab42 change.
Proteins predicting longitudinal CSF Ab42 change: effects of
baseline Ab42
The goal of this analysis was to test whether the predictive
effect of baseline proteins differed between subjects with or
without Ab plaque pathology at baseline. For this, we dichot-
omized the subjects into those with normal baseline Ab42
Table 1. Demographics of healthy control subjects
Characteristic Baseline Last follow-up
N (% male) 46 (54%) 46 (54%)
Age (year), mean (s.d.) 77 (5) 80 (5)
APOE e4 allele carriers (%) 24% 24%
Education (year), mean (s.d.) 16 (3) 16 (3)
MMSE, mean (s.d.) 29.4 (0  8) 29.0 (1.5)
ADAS-Cog, mean (s.d.) 6.1 (2.9) 6.6 (4.1)
ADAS-MOD, mean (s.d.) 9.3 (3.9) 10.7 (5.8)
CSF Ab42 (ng l 1), mean (s.d.) 211 (57) 195 (56)
CSF T-tau (ng l 1), mean (s.d.) 73 (30) 83 (30)
CSF P-tau (ng l 1), mean (s.d.) 25 (11) 36 (11)
N with three timepoints 23
N with four timepoints 23
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive
Behavior section; CSF, cerebrospinal fluid; MMSE, mini mental state
examination.
CSF Ab42, T-tau and P-tau calculated using fitted data from linear mixed
effect models (adjusted for age, sex, education and APOE) at baseline and
4-year follow-up.
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(Ab424192 ng l 1, n¼ 27, 59%, 12 female subjects, 1 APOE e4þ ,
mean age 77 years (range 72–88)) and reduced baseline Ab42
(n¼ 19, 41%, 9 female subjects, 10 APOE e4þ , mean age 79 years
(range 63–93)). Ab42 decreased with time in both these
subgroups (time as years after first sample; normal baseline
Ab42, b¼  4.9, s.e.¼ 1.3, Po0.001; reduced baseline Ab42,
b¼  3.2, s.e.¼ 0.68, Po0.001).
In subjects with normal baseline Ab42, several proteins were
significantly associated with longitudinal Ab42 reduction
(co-varying for age, sex, education and APOE, and adjusting for
multiple comparisons), including CgA (b¼  5.69, s.e.¼ 1.24,
P¼ 0.001), CD40 (b¼  5.01, s.e.¼ 1.46, P¼ 0.036), AXL
(b¼  4.55, s.e.¼ 1.38, P¼ 0.036), ACE (b¼  4.38, s.e.¼ 1.36,
P¼ 0.036), Log TNF-related apoptosis-inducing ligand receptor
(b¼  4.17, s.e.¼ 1.34, P¼ 0.039) and IL-3 (b¼  4.12, s.e.¼ 1.36,
P¼ 0.042). In subjects with reduced baseline Ab42, only TIMP1
(b¼  2.2, s.e.¼ 0.56, P¼ 0.020) was associated with longitudinal
Ab42 reduction.
Proteins associated with longitudinal CSF T-tau and P-tau increase
No protein was significantly associated with the change in T-tau or
P-tau (See Supplementary Tables 5 and 6).
Proteins associated with clinical outcome
Five of the 46 healthy control subjects progressed to MCI during
the study follow-up. Although the differences were not statistically
significant, these five subjects had lower baseline CSF Ab42 (mean
175 (s.d. 43) versus 215 (58) ng l 1), and higher baseline CSF T-tau
(85 (38) versus 72 (29) ng l 1) and P-tau (28 (16) versus 25
(11) ng l 1), than the 41 subjects who did not develop MCI.
We compared protein levels between stable controls and
developers by linear regression, adjusting for age, sex, APOE e4
and education. Matrix metalloproteinase 2 (MMP2) was the
only protein that was significantly different between developers
and stable controls (reduced in developers, b¼  1.64, s.e.¼ 0.43,
P¼ 0.03 adjusted for multiple comparisons, protein levels
centered and standardized).
Proteins associated with longitudinal CSF Ab42, T-tau and P-tau
changes in AD patients
To test whether CSF proteins were associated with longitudinal
change in CSF Ab42, T-tau or P-tau in subjects with advanced
disease, we also examined data from 16 patients with clinical AD
diagnosis (10 female patients, 13 APOE e4þ , mean age 75 (s.d. 6)
years). As expected and as shown previously in the ADNI cohort,4
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Figure 1. Longitudinal measurements of CSF Ab42, T-tau and P-tau. CSF Ab42, T-tau and P-tau in cognitively healthy controls followed up to
4 years, with three to four samples each. Thick lines are regression curves calculated using linear mixed effect models, adjusted for age, sex,
education and APOE. The changes over time (in years) were significant for Ab42 (b¼  4.11, s.e.¼ 0.77, Po0.0001), T-tau (b¼ 2.34, s.e.¼ 0.51,
Po0.0001) and P-tau (b¼ 2.76, s.e.¼ 0.49, Po0.0001).
Table 2. Effects of CSF proteins on longitudinal CSF Ab42 reduction in healthy controls
Linear mixed effect models
CSF biomarker b s.e. P Adjusted P
Log angiotensin-converting enzyme (ACE)  3.09 0.81 o0.001 0.009
Chromogranin A (CgA)  3.21 0.87 o0.001 0.009
AXL receptor tyrosine kinase (AXL)  3.14 0.86 o0.001 0.009
Log TNF-related apoptosis-inducing ligand receptor (TRAIL)  2.91 0.83 0.001 0.011
Log CD40 antigen (CD40)  3.14 0.91 0.001 0.012
Log macrophage colony-stimulating factor 1 (MCSF)  2.84 0.91 0.002 0.026
Log beta-2-microglobulin (B2M)  2.75 0.91 0.003 0.030
Log stem cell factor (SCF)  2.56 0.89 0.005 0.042
Log clusterin (CLU)  2.43 0.87 0.006 0.042
Log interleukin-3 (IL-3)  2.43 0.87 0.006 0.042
Linear mixed effect model data on b-coefficients, s.e. and P-values for the interaction terms between proteins and time (years from baseline). Adjusted P-values
were corrected for multiple comparisons using a false discovery rate correction. Data were adjusted for age, sex, education and APOE. Protein levels were
centered and standardized.
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these subjects had reduced baseline CSF Ab42 (mean 133 (s.d.
19) ng l 1), and elevated baseline CSF T-tau (131 (64) ng l 1) and
CSF P-tau (42 (13) ng l 1). In contrast to what we found in the
healthy controls, there were no significant changes over time in
CSF Ab42 (P¼ 0.90) or T-tau (P¼ 0.63), but there were significant
longitudinal increases in P-tau (b¼ 4.6, s.e.¼ 1.23, P¼ 0.0007) in
the 16 AD patients (linear mixed effect models, co-varied for age,
sex, education and APOE e4). After correcting for multiple
comparisons, no tested protein was significantly associated with
rates of change for CSF Ab42, T-tau or P-tau (data not shown).
DISCUSSION
The major findings of this study were as follows: (1) there were
significant longitudinal AD-like changes in CSF Ab42, T-tau and
P-tau—meaning Ab42 fell and T-tau/P-tau rose—in this cohort of
cognitively healthy elderly; (2) baseline levels of 10 CSF proteins,
primarily related to the Ab metabolism, microglial regulation or
synaptic function, significantly predicted longitudinal reduction in
Ab42 when using linear mixed effect models (and 11 proteins
when using ROC statistics); (3) several baseline proteins were
associated with longitudinal Ab42 changes in subjects with normal
baseline Ab42 but not in subjects with reduced baseline Ab42 and
(4) no baseline proteins predicted changes in T-tau or P-tau. The
finding that the predictive effects of baseline proteins on the
subsequent decline of Ab42 were different in subjects with normal
and reduced baseline CSF Ab42 levels suggests that some proteins
predict brain Ab plaque accumulation at a very early stage of AD,
prior to widespread plaque accumulation. The failure of baseline
proteins to predict longitudinal changes of T-tau and P-tau
suggests that these proteins are specifically predictive of Ab
pathology. Taken together, the evidence suggest that changes of
CSF proteins primarily related to Ab metabolism, microglial
regulation or synaptic functions most likely reflect pathological
alterations at very early stages of AD, and for some proteins even
prior to widespread neuritic plaque formation.
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Figure 2. Proteins significantly associated with CSF Ab42 change in healthy controls. The graph includes the baseline proteins (x axes) that
were significantly associated with CSF Ab42 rates, as tested using linear mixed effect models. y axes show CSF Ab42 reduction over 4 years
(ng l 1), adjusted for age, sex, education and APOE. Each dot represents a study participant.
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The first major finding was that cognitively healthy elderly
showed longitudinal changes in Ab42, P-tau and T-tau, partly
replicating a previous report using 3-year follow-up data from
ADNI-1 (the same subjects in this study) showing that healthy
controls manifested longitudinal decreases in Ab42 and increases
in P-tau.28 Cross-sectional studies have shown that cognitively
healthy subjects (or MCI subjects) at risk for future development of
AD dementia have altered Ab42, P-tau and T-tau several years
prior to symptoms, with reduced Ab42 appearing first.8 A few
previous studies have reported longitudinal measurements of
Ab42, P-tau and T-tau in cognitively healthy subjects.28–34 Most of
these have found no or only small changes of CSF Ab42, P-tau and
T-tau levels in cognitively healthy subjects,30–34 but these have
had fewer participants, shorter follow-up or fewer serial samples
than the present study. Our finding supports the use of Ab42,
T-tau and P-tau to track the development of AD-like pathology
prior to clinical symptoms.
Our second major finding was that 10 CSF proteins measured at
baseline significantly predicted longitudinal decrease in CSF Ab42
as determined using linear mixed effect models, and 11 proteins
as determined using ROC analysis (these sets of proteins largely
overlapped). There has been no published previous analysis
demonstrating the predictive effect of some CSF proteins on
longitudinal changes of CSF Ab42, T-tau or P-tau. The finding that
these CSF proteins predicted longitudinal decrease in CSF Ab42
indicate that they may be used as very early biomarkers of Ab
pathology and thereby possibly also of AD.
Furthermore, the findings that these proteins predict the
decrease in CSF Ab42 provide in vivo evidence that biological
pathways related to the Ab metabolism, microglia activity and
synaptic/neuronal function are involved in early Ab pathology (see
Supplementary Table 1 for references for the proteins described in
this paragraph). Several of the identified proteins are associated
with Ab metabolism in different ways. For example, CLU and
Cystatin C may bind Ab peptides and influence their aggregation,
ACE may degrade Ab peptides, and Stem Cell Factor and IL-3 may
protect against Ab deposits and toxicity. Several of the proteins
(including AXL, CD40, CgA, CLU, Cystatin C, MCSF and TIMP1) may
modulate microglial activity or have their expression promoted by
microglia, and some of the proteins (including ACE, B2M, CgA, IL-3
and TIMP1) have been described to be involved in synaptic or
other neuronal functions. For example, CgA has been proposed as
an indicator of presynaptic structures, and B2M and TIMP1 are
involved in synaptic plasticity. Several of the identified proteins
also have other associations with AD. For example, CLU is a major
AD risk gene. Some of the proteins have been reported to have
altered CSF levels in AD, with increased levels of MCSF and tumor
necrosis factor receptor 2, and decreased levels of TIMP1, CgA and
stem cell factor. Taken together, the evidence linking these
proteins with Ab, microglia and synaptic function, and other
evidence of their association with AD, provides additional support
for the view that these proteins are closely involved, and may
reflect causal events, in the pathophysiological events resulting in
AD pathology.
The third major finding was that several of the identified
proteins (CgA, CD40, AXL, ACE, TNF-related apoptosis-inducing
ligand receptor and IL-3) were associated with the future decrease
in CSF Ab42 only in subjects without any signs of Ab pathology at
baseline; however, only one tested protein (TIMP1) was associated
with further Ab42 accumulation in subjects in whom Ab pathology
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Figure 3. Proteins and quartiles of CSF Ab42 change in healthy controls. The graph includes the baseline proteins that significantly predicted
longitudinal reduction in CSF Ab42 in ROC analysis. For this analysis, subjects were ranked according to relative change in Ab42 over 4 years,
and subjects with most changes (1st quartile of subjects411.5% reduction, red boxes) were compared with subjects with least changes (4th
quartile of subjects o4.0% reduction, blue boxes). Subjects in the 2nd and 3rd quartiles (representing intermediate reductions) were not
included in the ROC analysis but are shown for comparison in yellow boxes (for most proteins, subjects in the 2nd and 3rd quartiles had
concentrations comparable to subjects in the 1st quartile). Baseline protein levels were centered and standardized.
CSF proteins predicting longitudinal CSF Ab42 reduction
N Mattsson et al
6
Translational Psychiatry (2013), 1 – 8 & 2013 Macmillan Publishers Limited
was already present. This suggests that these proteins reflect
biochemical processes occuring prior to widespread plaque
deposition because widespread plaques are reflected by low
CSF Ab42.1,7 Therefore, we interpret these results to suggest
that some of the identified proteins reflect pathophysiological
alternations that occur at the very earliest stages of AD. We also
tested 16 patients with AD dementia, in whom we found no
associations between baseline protein levels and change of CSF
Ab42, T-tau or P-tau. Although this result is difficult to interpret
because of the small number of subjects, it may support the
notion that the identified proteins mainly reflect brain processes
involved in the early stages of AD.
The fourth finding of this study was that there were no
significant associations between the baseline proteins and long-
itudinal T-tau/P-tau. This fits with the dynamic biomarker model,
in which changes in Ab42 (and thereby associated processes) are
more likely to be detected in early stages of the disease than
changes in T-tau and P-tau.19 One intriguing finding was that
several proteins were associated with baseline T-tau levels. Among
them were CgA, AXL and ACE, which themselves were strong
predictors of longitudinal CSF Ab42 reduction. One possible
explanation for the association between baseline T-tau and these
proteins is that they may share metabolic pathways unrelated to
Ab pathology. This view is supported by the fact that, although
CgA, ACE and AXL were strong predictors of longitudinal CSF
Ab42 reduction, baseline T-tau did not predict longitudinal CSF
Ab42 reduction.
The main limitation of this study is the relatively low sample
size, but this was balanced by the long follow-up time and
multiple samples from each subject. Our results may be biased by
the selection of proteins studied, included mainly because of
known associations with Ab metabolism, microglia activity or
synaptic function. It is possible that another set of proteins would
have shown stronger predictive effects on longitudinal change of
T-tau and P-tau. It is not known whether these proteins may help
identify patients at risk for future cognitive decline or AD. When
comparing protein levels between the 41 cognitively stable
controls and the 5 controls who progressed to MCI, the only
protein that was differently expressed between the groups was
MMP2, which was reduced in participants who developed MCI.
This is in agreement with previous studies, showing reduced CSF
MMP2 levels in AD.35 However, the small number of participants
who developed MCI in this study makes the negative results for
the other proteins difficult to interpret.
In sum, we found that baseline CSF proteins involved in the Ab
metabolism, microglial regulation and synaptic function predicted
longitudinal change in CSF Ab42 in cognitively healthy people.
Some of the proteins were only predictive in people with normal
CSF Ab42, suggesting that they may be used as biomarkers
predicting future development of Ab pathology in persons
without Ab pathology at testing. No proteins predicted increases
in CSF T-tau or P-tau, consistent with the view that these protein
changes occur prior to widespread plaque accumulation and
downstream axonal loss and tangle pathology. The results provide
in vivo evidence for pathological mechanisms related to early
Ab42 accumulation, and especially point to a role for early
alterations of the Ab metabolism and microglia activity. These
proteins may be useful tools to identify cognitively normal
subjects at risk for future Ab42 pathology, and subsequently AD.
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